Company Brings Suit to Enforce Right to Redeem 24% of Series A Preferred Stock PORTLAND, Ore., Oct. 1 /PRNewswire/ -- Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug delivery systems, today announced that it provided notice to redeem 164,950 shares of its Series A Convertible Preferred Stock held by Elan Pharmaceutical Investments, Ltd. for approximately $3.45 million. All shares of the Series A Preferred Stock currently outstanding are held by Elan and the shares to be redeemed represent approximately 24% of the outstanding shares. The Series A Preferred Stock accrues dividends at an annual rate of 9 percent and the preferred stock and all accrued dividends automatically convert to Bioject common stock in 2004 at a conversion price of $7.50 a share. Accordingly, the practical effect of this redemption is the repurchase by Bioject of 460,000 common equivalent shares for $7.50 a share. "This opportunity to redeem a portion of the Series A Convertible Preferred shares comes at a good time for the company," said Jim O'Shea, chairman, president and chief executive officer of Bioject. "We currently have the cash resources to fund this redemption; however, to conserve cash, our plan is to issue an equivalent number of common shares in the open market at a premium to the effective $7.50 redemption price." Elan responded to Bioject's notice by disputing Bioject's right to redeem this stock at this time and on these terms. To enforce its redemption rights, Bioject has filed a lawsuit in U.S. District Court in Oregon seeking an injunction and declaratory judgment to compel Elan to abide by the redemption provisions in Bioject's articles of incorporation. Regarding the dispute with Elan, O'Shea added: "Our right to redeem these shares was specifically negotiated with Elan. The redemption provides substantial value to our shareholders including an increase in liquidity, a decrease in the concentration of shares held by Elan, and a reduction in the annual dividend charge, which, last year was approximately $1.2 million. Accordingly, we intend to prosecute this lawsuit vigorously to enforce our rights." Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The company is focused on developing mutually beneficial agreements with leading pharmaceutical and biotechnology companies. Bioject's partners now include Amgen and Serono. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning products being developed by the Company, progress in clinical evaluations of the Company's products, possible enabling characteristics of the Company's products, collaborations with major pharmaceutical and biotechnology companies, current research and product development collaborations with Amgen and Serono, and clinical research collaborators. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Readers of this press release are referred to the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K and Form 10-Q for further discussions of factors which could affect future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change. More information can be found at Bioject's home page at: http://www.bioject.com . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X67119079 SOURCE Bioject Medical Technologies Inc. -0- 10/01/2001 /CONTACT: Jim O'Shea, Chairman, President & CEO of Bioject Medical Technologies Inc., +1-503-639-7221, ext. 565; or Jim Flanagan of IR Strategic Advisors, +1-781-863-1333, or firstname.lastname@example.org, for Bioject Medical Technologies Inc./ /Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/101750.html/ /Web site: http://www.bioject.com/ (BJCT) CO: Bioject Medical Technologies Inc.; Elan Pharmaceutical Investments, Ltd. ST: Oregon IN: MTC SU: LAW -0- Oct/01/2001 20:47 GMT
French Planes Carry Out First Strikes on Iraq Islamic State Targets
Bioject Exercises Series A Preferred Redemption Right
Press spacebar to pause and continue. Press esc to stop.